Rogier C. Buijsman

1.7k citations

49 papers · 1.3k indexed · h-index 20

Co-authors: Guido J.R. Zaman Joost C.M. Uitdehaag Jos de Man Martine B.W. Prinsen Nicole Willemsen‐Seegers C. A. A. VAN BOECKEL Martin de Kort Antoon M. van Doornmalen
Topics: Microtubule and mitosis dynamics (11 papers)Chronic Lymphocytic Leukemia Research (5 papers)Melanoma and MAPK Pathways (5 papers)
Cited by: Biological Psychiatry Aging Hematology
Journals: Proceedings of the National Academy of Sciences Angewandte Chemie International Edition Journal of Clinical Oncology
Partner nations: Netherlands Germany United Kingdom

In The Last Decade

Rogier C. Buijsman

48 papers receiving 1.2k citations

Peers

Countries citing papers authored by Rogier C. Buijsman

Since Specialization

Citations

This map shows the geographic impact of Rogier C. Buijsman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rogier C. Buijsman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rogier C. Buijsman more than expected).

Fields of papers citing papers by Rogier C. Buijsman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rogier C. Buijsman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rogier C. Buijsman. The network helps show where Rogier C. Buijsman may publish in the future.

Co-authorship network of co-authors of Rogier C. Buijsman

This figure shows the co-authorship network connecting the top 25 collaborators of Rogier C. Buijsman. A scholar is included among the top collaborators of Rogier C. Buijsman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rogier C. Buijsman. Rogier C. Buijsman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination 2024 ·Frontiers in Oncology ·(unknown),Nicole Forster,Felix Bachmann,(unknown),Paul M.J. McSheehy,(unknown),(unknown),Anna C. Groner,Mila Roceri,(unknown),(unknown),Nicole Willemsen‐Seegers,Jos de Man,(unknown),(unknown),Guido J.R. Zaman,Rogier C. Buijsman,Laurenz Kellenberger,Heidi A. Lane	1
2	183 (PB171): A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs) 2024 ·European Journal of Cancer ·Joost C.M. Uitdehaag,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Martine B.W. Prinsen,(unknown),Diep Vu,(unknown),(unknown),Rogier C. Buijsman	1
3	Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies 2023 ·Neuro-Oncology Advances ·(unknown),Anna Giczewska,(unknown),(unknown),Aslι Küçükosmanoğlu,(unknown),Rogier C. Buijsman,Pieter Wesseling,Laurine E. Wedekind,David P. Noske,Anna Supernat,David Bailey,Colin Watts,Thomas Würdinger,Bart A. Westerman	8
4	Pharmacological validation of TDO as a target for Parkinson’s disease 2021 ·FEBS Journal ·Paula Perez‐Pardo,(unknown),Nicole Willemsen‐Seegers,(unknown),(unknown),(unknown),Youri Adolfs,R. Jeroen Pasterkamp,(unknown),Antoon M. van Doornmalen,(unknown),(unknown),(unknown),Joost C.M. Uitdehaag,Jos de Man,Rogier C. Buijsman,Guido J.R. Zaman,Aletta D. Kraneveld	19
5	Mapping Arginase Expression with ¹⁸F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids 2021 ·Journal of Nuclear Medicine ·Gonçalo S. Clemente,Inês F. Antunes,(unknown),(unknown),Jürgen W. A. Sijbesma,Aren van Waarde,Rogier C. Buijsman,Nicole Willemsen‐Seegers,Reinoud Gosens,Herman Meurs,Alexander Dömlingꝉ,Philip H. Elsinga	4
6	High-Throughput Fluorescence-Based Activity Assay for Arginase-1 2020 ·SLAS DISCOVERY ·(unknown),Nicole Willemsen‐Seegers,Joost C.M. Uitdehaag,Jos de Man,(unknown),(unknown),Helma van den Hurk,Rogier C. Buijsman,Guido J.R. Zaman	7
7	Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158 2019 ·SHILAP Revista de lepidopterología ·(unknown),Joost C.M. Uitdehaag,Nicole Willemsen‐Seegers,(unknown),Jos de Man,Rogier C. Buijsman,Guido J.R. Zaman	34
8	Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017 2018 ·Molecular Cancer Therapeutics ·Joost C.M. Uitdehaag,(unknown),Jeroen A.D.M. de Roos,Martine B.W. Prinsen,(unknown),Nicole Willemsen‐Seegers,Yusuke Kawase,Masaaki Sawa,Jos de Man,Suzanne J.C. van Gerwen,Rogier C. Buijsman,Guido J.R. Zaman	20
9	TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers 2017 ·Molecular Cancer Therapeutics ·Guido J.R. Zaman,Jeroen A.D.M. de Roos,(unknown),Martine B.W. Prinsen,Jos de Man,Rogier C. Buijsman,Joost C.M. Uitdehaag	40
10	Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity 2017 ·Journal of Molecular Biology ·Joost C.M. Uitdehaag,Jos de Man,Nicole Willemsen‐Seegers,Martine B.W. Prinsen,(unknown),(unknown),(unknown),(unknown),Jeroen A.D.M. de Roos,Rogier C. Buijsman,Guido J.R. Zaman	44
11	Optimized Target Residence Time: Type I Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R‐Spine 2017 ·Angewandte Chemie International Edition ·(unknown),(unknown),(unknown),(unknown),Daniel Rauh,Guido J.R. Zaman,Nicole Willemsen‐Seegers,Rogier C. Buijsman,(unknown),Daniel Dauch,Lars Zender,Stefan Laufer	21
12	Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors 2016 ·Molecular Cancer Therapeutics ·Joost C.M. Uitdehaag,Jeroen A.D.M. de Roos,Martine B.W. Prinsen,Nicole Willemsen‐Seegers,(unknown),(unknown),Antoon M. van Doornmalen,(unknown),Masaaki Sawa,Suzanne J.C. van Gerwen,Jos de Man,Rogier C. Buijsman,Guido J.R. Zaman	12
13	MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia 2016 ·Leukemia ·Kirsten Canté-Barrett,J A P Spijkers-Hagelstein,Jessica G. C. A. M. Buijs-Gladdines,Joost C.M. Uitdehaag,Willem K. Smits,(unknown),Rogier C. Buijsman,Guido J.R. Zaman,Rob Pieters,Jules P.P. Meijerink	79
14	Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance 2016 ·Journal of Molecular Biology ·Nicole Willemsen‐Seegers,Joost C.M. Uitdehaag,Martine B.W. Prinsen,(unknown),Jos de Man,Masaaki Sawa,Yusuke Kawase,Rogier C. Buijsman,Guido J.R. Zaman	37
15	Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model 2015 ·Annals of Oncology ·Ana Maia,(unknown),Ute Boon,Aniek Janssen,Ji‐Ying Song,Manja Omerzu,(unknown),Martine B.W. Prinsen,Nicole Willemsen‐Seegers,(unknown),Antoon M. van Doornmalen,Joost C.M. Uitdehaag,Geert J.P.L. Kops,Jos Jonkers,Rogier C. Buijsman,Guido J.R. Zaman,René H. Medema	93
16	High-Throughput Fluorescence-Based Screening Assays for Tryptophan-Catabolizing Enzymes 2014 ·SLAS DISCOVERY ·(unknown),Antoon M. van Doornmalen,Joost C.M. Uitdehaag,Jos de Man,Rogier C. Buijsman,Guido J.R. Zaman	38
17	A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets 2012 ·British Journal of Pharmacology ·Joost C.M. Uitdehaag,Folkert Verkaar,(unknown),Jos de Man,Rogier C. Buijsman,Guido J.R. Zaman	80
18	Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity 2003 ·Journal of Thrombosis and Haemostasis ·G.M.T. Vogel,D.G. Meuleman,(unknown),Rogier C. Buijsman,(unknown),Martine J. Smit	15
19	Synthesis of heparin-like antithrombotics having perphosphorylated thrombin binding domains 1999 ·Bioorganic & Medicinal Chemistry ·Rogier C. Buijsman,Jan E. M. Basten,(unknown),Gijsbert A. van der Marel,C. A. A. VAN BOECKEL,Jacques H. van Boom	15
20	Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action 1999 ·Bioorganic & Medicinal Chemistry Letters ·Rogier C. Buijsman,Jan E. M. Basten,(unknown),Gijsbert A. van der Marel,C. A. A. VAN BOECKEL,Jacques H. van Boom	22

About Rogier C. Buijsman

Rogier C. Buijsman is a scholar working on Biological Psychiatry, Cell Biology and Biochemistry, having authored 49 papers that have together received 1.3k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Melanoma and MAPK Pathways (5 papers). The work is most often cited by research in Biological Psychiatry (128 citations), Aging (56 citations) and Hematology (152 citations). Rogier C. Buijsman has collaborated with scholars based in Netherlands, Germany and United Kingdom. Frequent co-authors include Guido J.R. Zaman, Joost C.M. Uitdehaag, Jos de Man, Martine B.W. Prinsen, Nicole Willemsen‐Seegers, C. A. A. VAN BOECKEL, Martin de Kort, Antoon M. van Doornmalen, Jeroen A.D.M. de Roos and Jules P.P. Meijerink. Their work appears in journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact